THORACIC SURGERY Anti-angiogenic agents in the treatment of non-small cell lung cancer
| Autor: | Rodryg Ramlau, Katarzyna Szyszka-Barth, Dariusz Stencel, Katarzyna Ramlau |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Oncology
medicine.medical_specialty Chemotherapy Bevacizumab business.industry medicine.medical_treatment Cancer Immunotherapy medicine.disease Vascular endothelial growth factor chemistry.chemical_compound chemistry Internal medicine medicine Surgery Nintedanib Cardiology and Cardiovascular Medicine business Lung cancer Tyrosine kinase medicine.drug |
| Zdroj: | Polish Journal of Cardio-Thoracic Surgery. 2:145-150 |
| ISSN: | 1731-5530 |
| Popis: | Lung cancer is the most common malignant neoplasm diagnosed worldwide. In Poland, in 2011, lung cancer was diagnosed in 14,522 men and 6,283 women. Morbidity and mortality are nearly equal, and lung cancer is still the most common cause of cancer-related death among men as well as among women. Approximately 80% of lung cancer cases are non-small-cell lung cancer. The most commonly applied chemotherapy regimens do not produce satisfactory effects. Oncological research is now focused on molecular targeted therapies; immunotherapy is also under evaluation. The formation of abnormal blood vessels has an enormous impact on the development and progression of a tumor. Bevacizumab is a monoclonal antibody which binds VEGF (vascular endothelial growth factor). A different group of drugs is constituted by small-molecule antiangiogenic tyrosine kinase inhibitors. These agents represent a different profile of side effects in comparison to chemotherapy. The mode of action, differing from cytotoxic drugs, requires renewed analysis as well as standardization of radiological response assessment criteria. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|